Skip to main content

Table 1 Baseline characteristics

From: Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

  Dapagliflozin (n = 14) Exenatide (n = 17) Dapagliflozin + exenatide (n = 12) Placebo (n = 14)
Age (years) 63.6 (8.5) 65.0 (5.8) 62.8 (7.7) 60.9 (6.9)
Female (n (%)) 4 (28.6) 6 (35.3) 4 (33.3) 4 (28.6)
Weight (kg) 98.5 (15.6) 96.6 (13.3) 90.5 (13.3) 99.1 (21.9)
BMI (kg/m2) 31.8 (3.4) 32.7 (5.1) 30.4 (3.8) 31.5 (5.9)
Diabetes duration (years) 7.0 [5.0,12.0] 10.0 [6, 18] 6.5 [3.0,7.0] 9.0 [7,11.0]
HbA1c (%)
(mmol/mol)
7.7 (0.5)
60.7 (5.8)
7.9 (0.8)
65.0 (11.1)
8.3 (1.3)
66.9 (14.2)
8.0 (1.0)
65.2 (11.7)
Hematocrit (%) 43.6 (0.9) 44.1 (0.8) 43.3 (0.5) 43.3 (0.9)
SBP (mmHg) 134.7 (2.2) 132.1 (2.7) 127.0 (2.9) 132.6 (3.3)
DBP (mmHg) 81.0 (1.5) 81.0 (1.8) 78.4 (2.0) 81.3 (1.7)
HR (bpm) 65.3 (2.9) 71.0 (2.4) 71.4 (2.3) 68.5 (2.4)
Pulse Pressure (mmHg) 53.6 (2.5) 51.1 (2.2) 48.7 (5.4) 51.3 (2.8)
Use of (n (%))
 Metformin 14 (100) 17 (100) 12 (100) 14 (100)
 SU derivative 4 (28.6) 6 (35.3) 3 (25.0) 8 (57.0)
 Beta blocker 4 (28.6) 4 (23.5) 1 (8.3) 2 (14.2)
 RAS inhibition 5 (35.7) 12 (70.6) 6 (54.5) 9 (64.3)
 ACE inhibitor 2 (40.0) 8 (66.7) 4 (66.7) 6 (66.7)
 ARB 3 (60.0) 4 (33.3) 2 (33.3) 3 (33.3)
Urine volume (ml/24 h) 1886.0 (836.4) 2216.4 (205.8) 2022.9 (848.4) 1610.3 (657.9)
Sodium excretion (mmol/24 h) 151.0 (69.0) 179.7 (59.2) 148.8 (67.5) 164.9 (68.2)
  1. Baseline characteristics of the per protocol population. Data are means ± SD or median [interquartile range] for continuous metrics, and number (%) for categorical characteristics
  2. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate (beats per minute); SU, Sulfonylurea; ACE, angiotensin converting enzyme; ARB, angiotensin-II receptor blocker